2021-01-07,CNS Pharmaceuticals to Present at the H.C. Wainwright BioConnect 2021 Conference
2020-12-28,CNS Pharmaceuticals Featured in Syndicated Broadcast Covering Recent FDA Approval of IND Application
2020-12-23,CNS Pharmaceuticals Announces Pricing of $10.0 Million Public Offering
2020-12-17,CNS Pharmaceuticals Announces Call to Discuss FDA IND Approval and Phase 2 Trial for Berubicin
2020-12-17,CNS Pharmaceuticals Announces FDA Approval of IND Application for its Brain Cancer Drug Candidate Berubicin
2020-12-16,InvestorBrandNetwork Announces Want Money Got Money Podcast with CNS Pharmaceuticals Inc. Chairman and CEO John Climaco
2020-11-24,CNS Pharmaceuticals Featured in Syndicated Broadcast Covering Recent Announcements for Glioblastoma Multiforme (GBM) Therapy
2020-11-19,CNS Pharmaceuticals and WPD Pharmaceuticals to Contribute Sponsorship to 2020 SNO Virtual Meeting
2020-11-18,CNS Pharmaceuticals to Participate in A.G.P.'s Virtual Healthcare Symposium
2020-11-17,CNS Pharmaceuticals Announces FDA Filing of IND for its Brain Cancer Drug Berubicin
2020-11-12,CNS Pharmaceuticals to Discuss Phase 2 Clinical Trial Design to be Submitted for FDA Review in Webcast at 4:30 PM ET Today
2020-10-29,CNS Pharmaceuticals Completes Manufacturing of Berubicin for Phase 2 Clinical Trial
2020-10-12,CNS Pharmaceuticals Highlights New Balancing Act Segment on Glioblastoma Airing on Lifetime TV
2020-10-09,CNS Pharmaceuticals Begins Manufacturing of Berubicin in Europe
2020-10-01,CNS Pharmaceuticals Achieves Critical Manufacturing Milestone
2020-09-24,CNS Pharmaceuticals and Image Analysis Group Partner to Further the Development of Berubicin
2020-09-17,CNS Pharmaceuticals to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
2020-09-11,CNS Pharmaceuticals to Present at the H.C. Wainwright & Co. 22nd Annual Global Investment Conference
2020-09-10,"Need To Know: CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) Insiders Have Been Buying Shares"
2020-09-03,CNS Pharmaceuticals Announces US Drug Manufacturing Milestones
2020-09-03,CNS Pharmaceuticals Announces US Drug Manufacturing Milestones
2020-08-27,"CNS Pharmaceuticals Announces Appointment of Dr. Patrick Wen, Director of Center for Neuro-Oncology at Dana-Farber Cancer Institute, to Science Advisory Board"
2020-08-25,CNS Provides FDA Update on IND Filing
2020-08-20,CNS Pharmaceuticals Engages CRO For Phase 2 Berubicin Clinical Trials
2020-08-11,"CNS Pharmaceuticals to Provide Second Quarter 2020 Business Update on Thursday, August 13, 2020"
2020-07-22,CNS Pharmaceuticals Recognizes Glioblastoma Awareness Day
2020-07-15,CNS Pharmaceuticals Completes Drug Product Manufacturing Strategy for Berubicin
2020-07-08,CNS Pharmaceuticals Completes Active Ingredient Shipments to Manufacturers
2020-06-30,CNS Pharmaceuticals Engages Berry Consultants to Advise Phase 2 Trial Design
2020-06-29,Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing
2020-06-23,"Virtual Conference for Life Sciences Companies Broadcast Live June 25, 2020"
2020-06-23,CNS To Present at the Life Sciences Investor Forum
2020-06-11,CNS Announces the FDA has Granted Orphan Drug Designation for Brain Cancer Drug Berubicin
2020-06-09,CNS Announces Highlights from Annual Meeting of Shareholders
2020-05-28,CNS Pharmaceuticals Announces Sponsored Research Agreement with MD Anderson for Potential Cancer Treatment Technologies
2020-05-27,"CNS Announces Common Stock Will Resume Trading on the NASDAQ on May 28, 2020"
2020-05-27,Nasdaq Scheduled Resumption in CNS Pharmaceuticals Inc.
2020-05-27,CNS Provides Update on Development Agreement for WP1122
2020-05-18,Nasdaq Halts CNS Pharmaceuticals Inc.
2020-05-18,"UPDATE: Moleculin Biotech, CNS Pharma     shares remain halted on Nasdaq"
2020-05-18,CNS Announces Nasdaq Trading Halt Pending Receipt of Additional Information
2020-05-11,CNS Provides Additional Comments Regarding Trading Halt
2020-05-08,Investor Alert: Kaplan Fox Investigates CNS Pharmaceuticals
2020-05-04,CNS Pharmaceuticals Announces Trading Halt
2020-04-30,WPD Pharmaceuticals and CNS Pharmaceuticals Identify Leading Polish Medical Institutions for Berubicin Phase 2 Clinical Trial
2020-04-30,CNS Pharmaceuticals and WPD Pharmaceuticals Identify Leading Polish Medical Institutions for Berubicin Phase 2 Clinical Trial
2020-04-24,"WPD Pharmaceuticals Announces FDA Application Under The Orphan Drug Act Was Submitted By License Partner for Brain Cancer Drug, Berubicin"
